entertainment -WSS

entertainment

author：comprehensive 2025-09-06 03:33:01 - browse：8126

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Removing probiotics from the NICU could threaten preemies' health

hotspot

WSS

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ambulance rides for just $100? Advisers want major billing fixes

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Jerome Adams on the need for new antivirals for Covid

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Executive Editor Rick Berke on STAT's 8th birthday

Wikipedia

entertainment

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA approves Recor Medical high blood pressure device

Apple is now the first public company to be valued at $3 trillion

Jerome Adams on the need for new antivirals for Covid

Jerome Adams on the need for new antivirals for Covid

Cancer drug shortages should be causing more outrage

Jerome Adams on the need for new antivirals for Covid

White House calls on federal agencies to crack down on AI abuses

New air purifier tech could be key to improving indoor air quality

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

knowledge

Study: New antibiotic targets gonorrhea as well as last existing drug

At least 13 dead in Texas as scorching temps continue

Removing probiotics from the NICU could threaten preemies' health

Drug repurposing or repositioning? The language matters

Diversify hospital leadership teams to protect BIPOC patient health

The high cost of giving birth even with insurance

knowledge

focus

hotspot

hotspot